Enteral Docosahexaenoic Acid and Retinopathy of Prematurity: A Randomized Clinical Trial

Mariela Bernabe-García, Raúl Villegas-Silva, Astrid Villavicencio-Torres, Philip C. Calder, Maricela Rodríguez-Cruz, Jorge Maldonado-Hernández, Denisse Macías-Loaiza, Mardia López-Alarcón, Patricia Inda-Icaza, Leonardo Cruz-Reynoso

Resultado de la investigación: Contribución a una revistaArtículo

2 Citas (Scopus)

Resumen

Background: Retinopathy of prematurity (ROP) is a disorder of the retina of low-birth-weight preterm infants that potentially leads to blindness. Docosahexaenoic acid (DHA), is protective in experimental models, but its administration as part of parenteral nutrition has shown inconsistent results. We test the effect of enteral DHA to prevent ROP and/or severity and to reduce hospital stay. Methods: This was a double-blind parallel clinical trial. Preterm infants (n = 110; 55 per group) with birth weight <1500 g but ≥1000 g were recruited in a neonatal intensive care unit. Infants were randomized to receive 75 mg of DHA/kg/d (DHA group) or high oleic sunflower oil (control group) for 14 days by enteral feeding. The effect of DHA was evaluated on any stage of ROP, severe ROP (stage ≥3) incidence, and hospital stay. Groups were compared with relative risk (RR) and 95% confidence interval (CI), Fisher's exact test, Student's t-test, or Mann-Whitney U-test, as appropriate. Logistic regression was applied to adjust for confounders. Results: There was no difference between the DHA and control groups in ROP risk (RR for DHA = 0.79; 95% CI, 0.49–1.27; P = 0.33). However, patients who received DHA showed lower risk for stage 3 ROP (RR for DHA = 0.66; 95% CI, 0.44–0.99; P = 0.03). After adjusting for confounders, this decreased risk remained significant (adjusted odds ratio = 0.10; 95% CI, 0.011–0.886; P = 0.04). Hospital stay was similar between groups. Conclusion: Enteral DHA may reduce the incidence of stage 3 ROP.

Idioma originalInglés
Páginas (desde-hasta)874-882
Número de páginas9
PublicaciónJournal of Parenteral and Enteral Nutrition
Volumen43
N.º7
DOI
EstadoPublicada - 1 sep 2019

Huella dactilar

Retinopathy of Prematurity
Docosahexaenoic Acids
Small Intestine
Randomized Controlled Trials
Confidence Intervals
Length of Stay
Premature Infants
Control Groups
Neonatal Intensive Care Units
Incidence
Parenteral Nutrition
Low Birth Weight Infant
Enteral Nutrition
Blindness
Nonparametric Statistics
Birth Weight
Retina
Theoretical Models
Logistic Models
Odds Ratio

Citar esto

Bernabe-García, M., Villegas-Silva, R., Villavicencio-Torres, A., Calder, P. C., Rodríguez-Cruz, M., Maldonado-Hernández, J., ... Cruz-Reynoso, L. (2019). Enteral Docosahexaenoic Acid and Retinopathy of Prematurity: A Randomized Clinical Trial. Journal of Parenteral and Enteral Nutrition, 43(7), 874-882. https://doi.org/10.1002/jpen.1497
Bernabe-García, Mariela ; Villegas-Silva, Raúl ; Villavicencio-Torres, Astrid ; Calder, Philip C. ; Rodríguez-Cruz, Maricela ; Maldonado-Hernández, Jorge ; Macías-Loaiza, Denisse ; López-Alarcón, Mardia ; Inda-Icaza, Patricia ; Cruz-Reynoso, Leonardo. / Enteral Docosahexaenoic Acid and Retinopathy of Prematurity : A Randomized Clinical Trial. En: Journal of Parenteral and Enteral Nutrition. 2019 ; Vol. 43, N.º 7. pp. 874-882.
@article{254c3b753eea48f5a64ee1527dc6c1b2,
title = "Enteral Docosahexaenoic Acid and Retinopathy of Prematurity: A Randomized Clinical Trial",
abstract = "Background: Retinopathy of prematurity (ROP) is a disorder of the retina of low-birth-weight preterm infants that potentially leads to blindness. Docosahexaenoic acid (DHA), is protective in experimental models, but its administration as part of parenteral nutrition has shown inconsistent results. We test the effect of enteral DHA to prevent ROP and/or severity and to reduce hospital stay. Methods: This was a double-blind parallel clinical trial. Preterm infants (n = 110; 55 per group) with birth weight <1500 g but ≥1000 g were recruited in a neonatal intensive care unit. Infants were randomized to receive 75 mg of DHA/kg/d (DHA group) or high oleic sunflower oil (control group) for 14 days by enteral feeding. The effect of DHA was evaluated on any stage of ROP, severe ROP (stage ≥3) incidence, and hospital stay. Groups were compared with relative risk (RR) and 95{\%} confidence interval (CI), Fisher's exact test, Student's t-test, or Mann-Whitney U-test, as appropriate. Logistic regression was applied to adjust for confounders. Results: There was no difference between the DHA and control groups in ROP risk (RR for DHA = 0.79; 95{\%} CI, 0.49–1.27; P = 0.33). However, patients who received DHA showed lower risk for stage 3 ROP (RR for DHA = 0.66; 95{\%} CI, 0.44–0.99; P = 0.03). After adjusting for confounders, this decreased risk remained significant (adjusted odds ratio = 0.10; 95{\%} CI, 0.011–0.886; P = 0.04). Hospital stay was similar between groups. Conclusion: Enteral DHA may reduce the incidence of stage 3 ROP.",
keywords = "DHA, ROP, neonate, omega-3 fatty acids, premature infant, preterm, retinopathy",
author = "Mariela Bernabe-Garc{\'i}a and Ra{\'u}l Villegas-Silva and Astrid Villavicencio-Torres and Calder, {Philip C.} and Maricela Rodr{\'i}guez-Cruz and Jorge Maldonado-Hern{\'a}ndez and Denisse Mac{\'i}as-Loaiza and Mardia L{\'o}pez-Alarc{\'o}n and Patricia Inda-Icaza and Leonardo Cruz-Reynoso",
year = "2019",
month = "9",
day = "1",
doi = "10.1002/jpen.1497",
language = "Ingl{\'e}s",
volume = "43",
pages = "874--882",
journal = "Journal of Parenteral and Enteral Nutrition",
issn = "0148-6071",
publisher = "John Wiley & Sons Inc.",
number = "7",

}

Bernabe-García, M, Villegas-Silva, R, Villavicencio-Torres, A, Calder, PC, Rodríguez-Cruz, M, Maldonado-Hernández, J, Macías-Loaiza, D, López-Alarcón, M, Inda-Icaza, P & Cruz-Reynoso, L 2019, 'Enteral Docosahexaenoic Acid and Retinopathy of Prematurity: A Randomized Clinical Trial', Journal of Parenteral and Enteral Nutrition, vol. 43, n.º 7, pp. 874-882. https://doi.org/10.1002/jpen.1497

Enteral Docosahexaenoic Acid and Retinopathy of Prematurity : A Randomized Clinical Trial. / Bernabe-García, Mariela; Villegas-Silva, Raúl; Villavicencio-Torres, Astrid; Calder, Philip C.; Rodríguez-Cruz, Maricela; Maldonado-Hernández, Jorge; Macías-Loaiza, Denisse; López-Alarcón, Mardia; Inda-Icaza, Patricia; Cruz-Reynoso, Leonardo.

En: Journal of Parenteral and Enteral Nutrition, Vol. 43, N.º 7, 01.09.2019, p. 874-882.

Resultado de la investigación: Contribución a una revistaArtículo

TY - JOUR

T1 - Enteral Docosahexaenoic Acid and Retinopathy of Prematurity

T2 - A Randomized Clinical Trial

AU - Bernabe-García, Mariela

AU - Villegas-Silva, Raúl

AU - Villavicencio-Torres, Astrid

AU - Calder, Philip C.

AU - Rodríguez-Cruz, Maricela

AU - Maldonado-Hernández, Jorge

AU - Macías-Loaiza, Denisse

AU - López-Alarcón, Mardia

AU - Inda-Icaza, Patricia

AU - Cruz-Reynoso, Leonardo

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Background: Retinopathy of prematurity (ROP) is a disorder of the retina of low-birth-weight preterm infants that potentially leads to blindness. Docosahexaenoic acid (DHA), is protective in experimental models, but its administration as part of parenteral nutrition has shown inconsistent results. We test the effect of enteral DHA to prevent ROP and/or severity and to reduce hospital stay. Methods: This was a double-blind parallel clinical trial. Preterm infants (n = 110; 55 per group) with birth weight <1500 g but ≥1000 g were recruited in a neonatal intensive care unit. Infants were randomized to receive 75 mg of DHA/kg/d (DHA group) or high oleic sunflower oil (control group) for 14 days by enteral feeding. The effect of DHA was evaluated on any stage of ROP, severe ROP (stage ≥3) incidence, and hospital stay. Groups were compared with relative risk (RR) and 95% confidence interval (CI), Fisher's exact test, Student's t-test, or Mann-Whitney U-test, as appropriate. Logistic regression was applied to adjust for confounders. Results: There was no difference between the DHA and control groups in ROP risk (RR for DHA = 0.79; 95% CI, 0.49–1.27; P = 0.33). However, patients who received DHA showed lower risk for stage 3 ROP (RR for DHA = 0.66; 95% CI, 0.44–0.99; P = 0.03). After adjusting for confounders, this decreased risk remained significant (adjusted odds ratio = 0.10; 95% CI, 0.011–0.886; P = 0.04). Hospital stay was similar between groups. Conclusion: Enteral DHA may reduce the incidence of stage 3 ROP.

AB - Background: Retinopathy of prematurity (ROP) is a disorder of the retina of low-birth-weight preterm infants that potentially leads to blindness. Docosahexaenoic acid (DHA), is protective in experimental models, but its administration as part of parenteral nutrition has shown inconsistent results. We test the effect of enteral DHA to prevent ROP and/or severity and to reduce hospital stay. Methods: This was a double-blind parallel clinical trial. Preterm infants (n = 110; 55 per group) with birth weight <1500 g but ≥1000 g were recruited in a neonatal intensive care unit. Infants were randomized to receive 75 mg of DHA/kg/d (DHA group) or high oleic sunflower oil (control group) for 14 days by enteral feeding. The effect of DHA was evaluated on any stage of ROP, severe ROP (stage ≥3) incidence, and hospital stay. Groups were compared with relative risk (RR) and 95% confidence interval (CI), Fisher's exact test, Student's t-test, or Mann-Whitney U-test, as appropriate. Logistic regression was applied to adjust for confounders. Results: There was no difference between the DHA and control groups in ROP risk (RR for DHA = 0.79; 95% CI, 0.49–1.27; P = 0.33). However, patients who received DHA showed lower risk for stage 3 ROP (RR for DHA = 0.66; 95% CI, 0.44–0.99; P = 0.03). After adjusting for confounders, this decreased risk remained significant (adjusted odds ratio = 0.10; 95% CI, 0.011–0.886; P = 0.04). Hospital stay was similar between groups. Conclusion: Enteral DHA may reduce the incidence of stage 3 ROP.

KW - DHA

KW - ROP

KW - neonate

KW - omega-3 fatty acids

KW - premature infant

KW - preterm

KW - retinopathy

UR - http://www.scopus.com/inward/record.url?scp=85059573679&partnerID=8YFLogxK

U2 - 10.1002/jpen.1497

DO - 10.1002/jpen.1497

M3 - Artículo

AN - SCOPUS:85059573679

VL - 43

SP - 874

EP - 882

JO - Journal of Parenteral and Enteral Nutrition

JF - Journal of Parenteral and Enteral Nutrition

SN - 0148-6071

IS - 7

ER -

Bernabe-García M, Villegas-Silva R, Villavicencio-Torres A, Calder PC, Rodríguez-Cruz M, Maldonado-Hernández J y otros. Enteral Docosahexaenoic Acid and Retinopathy of Prematurity: A Randomized Clinical Trial. Journal of Parenteral and Enteral Nutrition. 2019 sep 1;43(7):874-882. https://doi.org/10.1002/jpen.1497